|
ATE180280T1
(de)
*
|
1991-03-05 |
1999-06-15 |
Wellcome Found |
Expression rekombinanter proteine in attenuierten bakterien
|
|
US5981724A
(en)
*
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US5716805A
(en)
*
|
1991-10-25 |
1998-02-10 |
Immunex Corporation |
Methods of preparing soluble, oligomeric proteins
|
|
US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
KR100283541B1
(ko)
|
1991-10-25 |
2001-03-02 |
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 |
신규 사이토킨
|
|
US7405270B2
(en)
*
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
CA2143299A1
(en)
*
|
1992-09-04 |
1994-03-17 |
University Of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
|
US5565321A
(en)
*
|
1993-01-22 |
1996-10-15 |
Immunex Corporation |
Detection of mutations in a CD40 ligand gene
|
|
WO1995014487A1
(en)
|
1993-11-24 |
1995-06-01 |
The Australian National University |
Treatment of viral disease with cd40l peptide
|
|
DK0763057T3
(da)
*
|
1994-04-28 |
2006-03-27 |
Boehringer Ingelheim Pharma |
Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
|
|
AU699291B2
(en)
|
1995-03-01 |
1998-11-26 |
Immunex Corporation |
Method for stimulating an immune response
|
|
MX9709447A
(es)
|
1995-06-07 |
1998-02-28 |
Immunex Corp |
Nueva muteina cd4ol.
|
|
US6479258B1
(en)
*
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
*
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
*
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
JP2001526241A
(ja)
|
1997-12-19 |
2001-12-18 |
イミュネックス・コーポレーション |
Ｈｉｖ感染に対する感受性を低下させるための方法
|
|
GB9806449D0
(en)
*
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
*
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
WO2000014240A2
(en)
*
|
1998-09-04 |
2000-03-16 |
Creatogen Aktiengesellschaft |
Attenuated salmonella sp12 mutants as antigen carriers
|
|
US7300774B1
(en)
*
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
JP2003508016A
(ja)
|
1999-04-16 |
2003-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
|
EP1246643A4
(en)
*
|
1999-10-14 |
2005-05-11 |
Jeffery A Ledbetter |
DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
|
|
MXPA00012796A
(es)
*
|
1999-12-28 |
2002-05-23 |
Akzo Nobel Nv |
Vacuna de salmonella.
|
|
DE60136334D1
(en)
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
AU5695701A
(en)
*
|
2000-03-17 |
2001-10-03 |
Upjohn Co |
Salmonella vaccine materials and methods
|
|
GB0015426D0
(en)
*
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
AU2001273009A1
(en)
|
2000-06-26 |
2002-01-08 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
EP1407004B1
(en)
*
|
2001-05-15 |
2009-08-05 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease
|
|
AU2002316560B2
(en)
*
|
2001-07-06 |
2008-05-01 |
Abic Biological Laboratories Ltd |
Nucleic acids encoding a recombinant 250 kDa antigen from Sporozoites/Merozoites of Eimeria maxima and their uses
|
|
ZA200400479B
(en)
*
|
2001-07-06 |
2006-05-31 |
Abic Biolog Lab Teva |
Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
US7378089B2
(en)
|
2001-10-02 |
2008-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy for the prevention of autoimmune disease
|
|
PL208287B1
(pl)
*
|
2001-12-21 |
2011-04-29 |
Immunex Corp |
Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
|
|
KR100965026B1
(ko)
*
|
2002-02-13 |
2010-06-21 |
이뮤놀로지 래보러토리스 인코포레이티드 |
미생물 감염증을 치료하기 위한 조성물 및 방법
|
|
US6923958B2
(en)
*
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
WO2003096812A1
(en)
*
|
2002-04-15 |
2003-11-27 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
*
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
*
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
WO2005058950A2
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US8513008B2
(en)
*
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US20080145931A1
(en)
|
2004-10-07 |
2008-06-19 |
Argos Therapeutics, Inc. |
Mature Dendritic Cell Compositions and Methods of Culturing Same
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
JP2009511452A
(ja)
|
2005-10-07 |
2009-03-19 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
|
|
AU2006311752A1
(en)
*
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
DE102005054643B3
(de)
|
2005-11-10 |
2007-02-15 |
Assa Abloy Sicherheitstechnik Gmbh |
Schließzylinder
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
CU23576A1
(es)
*
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
*
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
FR2898905B1
(fr)
*
|
2006-03-24 |
2008-05-09 |
Rhodia Recherches & Tech |
Composition polyisocyanate a proprietes anti-chocs ameliorees
|
|
US20090246220A1
(en)
*
|
2006-08-28 |
2009-10-01 |
Ertl Hildegund C J |
Constructs for enhancing immune responses
|
|
EP2857038B1
(en)
|
2006-09-18 |
2019-04-10 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CN101024076B
(zh)
*
|
2007-03-29 |
2010-08-18 |
中国农业大学 |
球虫的新用途
|
|
ES2657801T3
(es)
*
|
2007-07-10 |
2018-03-06 |
Apogenix Ag |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
US9125854B2
(en)
*
|
2007-10-30 |
2015-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
PT2214701T
(pt)
|
2007-11-01 |
2016-11-02 |
Univ Guelph |
Composições e métodos de potenciar respostas imunes a eimeria
|
|
EP3103875A1
(en)
*
|
2008-07-21 |
2016-12-14 |
Apogenix AG |
Tnfsf single chain molecules
|
|
US8316310B2
(en)
|
2008-08-05 |
2012-11-20 |
International Business Machines Corporation |
System and method for human identification proof for use in virtual environments
|
|
EP2184229B1
(en)
*
|
2008-11-11 |
2012-10-17 |
AGUSTAWESTLAND S.p.A. |
Helicopter rotor
|
|
US20100150958A1
(en)
*
|
2008-12-15 |
2010-06-17 |
Vectogen Pty Ltd. |
Methods and Compositions for Use of a Coccidiosis Vaccine
|
|
NO2525817T3
(enExample)
*
|
2010-01-21 |
2018-01-06 |
|
|
|
KR20220116585A
(ko)
*
|
2011-10-11 |
2022-08-23 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
|
US20140079704A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
BI-Specific Diabodies For Masking And Targeting Vaccines
|
|
AU2013338153B2
(en)
*
|
2012-10-29 |
2018-06-21 |
The Board Of Trustees Of The University Of Arkansas |
Novel mucosal adjuvants and delivery systems
|
|
EP2956165B1
(en)
*
|
2013-02-14 |
2019-09-11 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
|
|
CN105142653B
(zh)
*
|
2013-03-15 |
2019-11-15 |
阿肯色大学评议会 |
增强对肠病原体免疫应答的组合物和方法
|
|
CN106535932A
(zh)
*
|
2014-06-05 |
2017-03-22 |
阿肯色大学评议会 |
抗体引导的疫苗和用于产生快速成熟的免疫应答的方法
|
|
WO2016054225A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Stc.Unm |
Plasmid delivery in the treatment of cancer and other disease states
|
|
WO2017172981A2
(en)
*
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
UA123111C2
(uk)
*
|
2016-05-27 |
2021-02-17 |
Еббві Байотерапьютікс Інк. |
Антитіло до cd40 та його застосування
|
|
IL308824A
(en)
*
|
2016-08-17 |
2024-01-01 |
Factor Bioscience Inc |
Nucleic acid products and methods of administration thereof
|